Sarepta Therapeutics (NASDAQ:SRPT) Rating Reiterated by Needham & Company LLC

Needham & Company LLC reissued their buy rating on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a research report report published on Thursday morning, Benzinga reports. The firm currently has a $235.00 price objective on the biotechnology company’s stock.

SRPT has been the topic of several other reports. Wedbush reissued an outperform rating and set a $224.00 price objective on shares of Sarepta Therapeutics in a research report on Thursday, February 29th. Piper Sandler reissued an overweight rating and set a $157.00 price target on shares of Sarepta Therapeutics in a report on Friday, June 21st. Royal Bank of Canada upped their price objective on Sarepta Therapeutics from $142.00 to $182.00 and gave the company a sector perform rating in a research note on Friday, June 21st. Morgan Stanley reiterated an overweight rating and issued a $165.00 target price on shares of Sarepta Therapeutics in a research note on Friday, June 21st. Finally, Evercore ISI upped their price target on Sarepta Therapeutics from $139.00 to $185.00 and gave the stock an in-line rating in a research note on Monday, June 24th. Five research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of Moderate Buy and an average target price of $185.06.

Sarepta Therapeutics Price Performance

Shares of SRPT opened at $158.00 on Thursday. The company has a debt-to-equity ratio of 1.18, a current ratio of 4.05 and a quick ratio of 3.44. Sarepta Therapeutics has a 1-year low of $55.25 and a 1-year high of $173.25. The stock has a market cap of $14.93 billion, a PE ratio of 1,436.36 and a beta of 0.96. The firm has a fifty day moving average price of $129.74 and a 200 day moving average price of $122.45.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its earnings results on Wednesday, May 1st. The biotechnology company reported $0.73 earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.84. Sarepta Therapeutics had a return on equity of 2.20% and a net margin of 1.20%. The business had revenue of $413.50 million during the quarter, compared to the consensus estimate of $375.52 million. During the same period in the previous year, the business earned ($1.44) EPS. The business’s quarterly revenue was up 63.1% on a year-over-year basis. As a group, sell-side analysts anticipate that Sarepta Therapeutics will post 3.71 EPS for the current year.

Insider Activity at Sarepta Therapeutics

In other Sarepta Therapeutics news, insider Dallan Murray sold 3,635 shares of the business’s stock in a transaction on Thursday, May 2nd. The stock was sold at an average price of $140.00, for a total transaction of $508,900.00. Following the sale, the insider now directly owns 18,125 shares in the company, valued at $2,537,500. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other Sarepta Therapeutics news, EVP Ryan Edward Brown sold 38,957 shares of Sarepta Therapeutics stock in a transaction dated Tuesday, June 25th. The shares were sold at an average price of $161.61, for a total transaction of $6,295,840.77. Following the completion of the transaction, the executive vice president now owns 17,129 shares in the company, valued at $2,768,217.69. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Dallan Murray sold 3,635 shares of the stock in a transaction that occurred on Thursday, May 2nd. The shares were sold at an average price of $140.00, for a total transaction of $508,900.00. Following the completion of the sale, the insider now owns 18,125 shares in the company, valued at $2,537,500. The disclosure for this sale can be found here. Insiders sold 50,451 shares of company stock valued at $8,086,386 in the last ninety days. Corporate insiders own 7.70% of the company’s stock.

Institutional Investors Weigh In On Sarepta Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of SRPT. Principal Securities Inc. acquired a new position in shares of Sarepta Therapeutics in the fourth quarter worth $26,000. Mather Group LLC. acquired a new position in Sarepta Therapeutics in the 1st quarter valued at about $28,000. Riggs Asset Managment Co. Inc. lifted its holdings in Sarepta Therapeutics by 125.0% in the 1st quarter. Riggs Asset Managment Co. Inc. now owns 225 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 125 shares in the last quarter. Cary Street Partners Investment Advisory LLC boosted its stake in shares of Sarepta Therapeutics by 154.0% during the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 254 shares of the biotechnology company’s stock worth $31,000 after purchasing an additional 154 shares during the last quarter. Finally, New Covenant Trust Company N.A. purchased a new stake in shares of Sarepta Therapeutics during the first quarter worth about $32,000. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.